
Audio By Carbonatix
Breast cancer can resurface after remaining dormant for 15 years following successful treatment, a study has found.
Women with large tumours and cancer that had spread to the lymph nodes had the highest 40% risk of it coming back.
Researchers writing in the New England Journal of Medicine said extending treatment with hormone therapy could reduce the risk of it recurring.
Scientists analysed the progress of 63,000 women for 20 years.
All had the most common form of breast cancer.
This is a type fuelled by the hormone oestrogen which can stimulate cancer cells to grow and divide.
Every patient received treatments such as tamoxifen or aromatase inhibitors which block the effects of oestrogen or shut off the hormone's supply.
Although after five years of treatment their cancers had gone, over the next 15 years a steady number of women found that their cancer spread throughout their body - some up to 20 years after diagnosis.
Women who originally had large tumours and cancer that had spread to four or more lymph nodes were at highest risk of the cancer returning the next 15 years, the study said.
Women with small, low-grade cancers and no spread to the lymph nodes had a much lower 10% risk of cancer spread over that time.
'Remarkable'
Lead researcher Dr Hongchao Pan, from University of Oxford, said: "It is remarkable that breast cancer can remain dormant for so long and then spread many years later, with this risk remaining the same year after year and still strongly related to the size of the original cancer and whether it had spread to the (lymph) nodes."
Doctors have long known that five years of tamoxifen reduces the risk of recurrence by about a third in the five years after stopping treatment.
Recent research has suggested that extending hormone therapy to 10 years may be more effective at preventing breast cancer recurrence and death.

But there are side effects with hormone treatments which can affect patients' quality of life and cause them to stop taking the pills.
These include menopausal symptoms, osteporosis, joint pain and carpal tunnel syndrome.
Prof Arnie Purushotham, senior clinical adviser at Cancer Research UK, which funded the study, said that since the research began, new drugs had been used to treat breast cancer and those worked in different ways to tamoxifen.
He said: "It's vital that work continues to better predict which cancers might return.
"We also need to know what the difference for women might be in taking hormone therapies for 10 years instead of five, the side effects and how this affects patients' quality of life."
Latest Stories
-
‘It doesn’t add up’ – Minority questions PURC’s tariff increase
30 minutes -
High Court affirms ICAG’s sole authority to regulate accountancy profession
1 hour -
A restored banking license difficult to resume operation; once collapsed ends its story
2 hours -
Kojo Mensa-Wilmot – a Molecular Biologist and Parasitologist
2 hours -
THE LAW 101: The burden of proof and the presumption of innocence – Lessons from London
2 hours -
UN says it will evacuate sailors stranded in Strait of Hormuz, as Rubio warns against tolls
2 hours -
Police arrest 186 suspects in major crackdown on human trafficking, organised crime in Ashanti Region
2 hours -
The Inconvenient Truth: Nations do not industrialise by accident—they industrialise by procurement design
2 hours -
Nandom Community Bank records GH₵81.8m asset growth as stakeholders rally for urgent recapitalisation
2 hours -
GIZ, Guinness Ghana sign MoU to boost sorghum output, target 30,000 farmers, 150 jobs in northern Ghana
2 hours -
Partey, Inaki Williams start as Queiroz makes four changes for England clash
3 hours -
LUV FACT-CHECK: NPP did not demand retraction from Kennedy Agyapong over Afari Hospital criticism
3 hours -
80 children, 1 room: Bugbelle gets room for hope
3 hours -
VRA warns public over recruitment scam, says it does not charge fees
3 hours -
Accra dons national colours as fans rally behind Black Stars ahead of England clash
3 hours